Cargando…
Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam
OBJECTIVES: Mechanisms of wound healing are often impaired in patients with osteonecrosis of the jaw (ONJ). According to the guidelines for the treatment of this disease, early surgical intervention is indicated. However, surgery often faces complications such as wound healing disorders. The applica...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708756/ https://www.ncbi.nlm.nih.gov/pubmed/35941396 http://dx.doi.org/10.1007/s00784-022-04663-y |
_version_ | 1784841008140255232 |
---|---|
author | Straub, Anton Vollmer, Andreas Lâm, Thiên-Trí Brands, Roman C. Stapf, Maximilian Scherf-Clavel, Oliver Bittrich, Max Fuchs, Andreas Kübler, Alexander C. Hartmann, Stefan |
author_facet | Straub, Anton Vollmer, Andreas Lâm, Thiên-Trí Brands, Roman C. Stapf, Maximilian Scherf-Clavel, Oliver Bittrich, Max Fuchs, Andreas Kübler, Alexander C. Hartmann, Stefan |
author_sort | Straub, Anton |
collection | PubMed |
description | OBJECTIVES: Mechanisms of wound healing are often impaired in patients with osteonecrosis of the jaw (ONJ). According to the guidelines for the treatment of this disease, early surgical intervention is indicated. However, surgery often faces complications such as wound healing disorders. The application of platelet-rich fibrin (PRF) after necrosectomy between bone and mucosa may constitute a promising approach to improve surgical results. An aspect that was not investigated until now is that PRF acts as a “bio-carrier” for antibiotics previously applied intravenously. MATERIALS AND METHODS: We investigated the antimicrobial properties of PRF in 24 patients presenting ONJ undergoing systemic antibiosis with ampicillin/sulbactam. We measured the concentration of ampicillin/sulbactam in plasma and PRF and performed agar diffusion tests. Ampicillin/sulbactam was applied intravenously to the patient 10 minutes for blood sampling for PRF. No further incorporation of patients’ blood or PRF product with antibiotic drugs was obtained. Four healthy patients served as controls. RESULTS: Our results revealed that PRF is highly enriched with ampicillin/sulbactam that is released to the environment. The antibiotic concentration in PRF was comparable to the plasma concentration of ampicillin/sulbactam. The inhibition zone (IZ) of PRF was comparable to the standard ampicillin/sulbactam discs used in sensitivity testing. CONCLUSIONS: The results of our study demonstrated that PRF is a reliable bio-carrier for systemic applied antibiotics and exhibits a large antimicrobial effect. CLINICAL RELEVANCE: We describe a clinically useful feature of PRF as a bio-carrier for antibiotics. Especially when applied to poorly perfused tissues and bone such as in ONJ, the local release of antibiotics can reduce wound healing disorders like infections. |
format | Online Article Text |
id | pubmed-9708756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-97087562022-12-01 Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam Straub, Anton Vollmer, Andreas Lâm, Thiên-Trí Brands, Roman C. Stapf, Maximilian Scherf-Clavel, Oliver Bittrich, Max Fuchs, Andreas Kübler, Alexander C. Hartmann, Stefan Clin Oral Investig Original Article OBJECTIVES: Mechanisms of wound healing are often impaired in patients with osteonecrosis of the jaw (ONJ). According to the guidelines for the treatment of this disease, early surgical intervention is indicated. However, surgery often faces complications such as wound healing disorders. The application of platelet-rich fibrin (PRF) after necrosectomy between bone and mucosa may constitute a promising approach to improve surgical results. An aspect that was not investigated until now is that PRF acts as a “bio-carrier” for antibiotics previously applied intravenously. MATERIALS AND METHODS: We investigated the antimicrobial properties of PRF in 24 patients presenting ONJ undergoing systemic antibiosis with ampicillin/sulbactam. We measured the concentration of ampicillin/sulbactam in plasma and PRF and performed agar diffusion tests. Ampicillin/sulbactam was applied intravenously to the patient 10 minutes for blood sampling for PRF. No further incorporation of patients’ blood or PRF product with antibiotic drugs was obtained. Four healthy patients served as controls. RESULTS: Our results revealed that PRF is highly enriched with ampicillin/sulbactam that is released to the environment. The antibiotic concentration in PRF was comparable to the plasma concentration of ampicillin/sulbactam. The inhibition zone (IZ) of PRF was comparable to the standard ampicillin/sulbactam discs used in sensitivity testing. CONCLUSIONS: The results of our study demonstrated that PRF is a reliable bio-carrier for systemic applied antibiotics and exhibits a large antimicrobial effect. CLINICAL RELEVANCE: We describe a clinically useful feature of PRF as a bio-carrier for antibiotics. Especially when applied to poorly perfused tissues and bone such as in ONJ, the local release of antibiotics can reduce wound healing disorders like infections. Springer Berlin Heidelberg 2022-08-09 2022 /pmc/articles/PMC9708756/ /pubmed/35941396 http://dx.doi.org/10.1007/s00784-022-04663-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Straub, Anton Vollmer, Andreas Lâm, Thiên-Trí Brands, Roman C. Stapf, Maximilian Scherf-Clavel, Oliver Bittrich, Max Fuchs, Andreas Kübler, Alexander C. Hartmann, Stefan Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam |
title | Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam |
title_full | Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam |
title_fullStr | Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam |
title_full_unstemmed | Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam |
title_short | Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam |
title_sort | evaluation of advanced platelet-rich fibrin (prf) as a bio-carrier for ampicillin/sulbactam |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708756/ https://www.ncbi.nlm.nih.gov/pubmed/35941396 http://dx.doi.org/10.1007/s00784-022-04663-y |
work_keys_str_mv | AT straubanton evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT vollmerandreas evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT lamthientri evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT brandsromanc evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT stapfmaximilian evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT scherfclaveloliver evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT bittrichmax evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT fuchsandreas evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT kubleralexanderc evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam AT hartmannstefan evaluationofadvancedplateletrichfibrinprfasabiocarrierforampicillinsulbactam |